Hypoglycemics, SGLT2 Inhibitors
Therapeutic Class Review (TCR)

September 1, 2016

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management.

All requests for permission should be mailed to:

Magellan Rx Management
Attention: Legal Department
6950 Columbia Gateway Drive
Columbia, Maryland 21046

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
**FDA-APPROVED INDICATIONS**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>canagliflozin (Invokana®)</td>
<td>Janssen</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</td>
</tr>
<tr>
<td>canagliflozin/metformin (Invokamet®)</td>
<td>Janssen</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate</td>
</tr>
<tr>
<td>canagliflozin/metformin (Invokamet® XR)</td>
<td>Janssen</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate</td>
</tr>
<tr>
<td>dapagliflozin (Farxiga®)</td>
<td>AstraZeneca</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</td>
</tr>
<tr>
<td>dapagliflozin/metformin ER (Xigduo® XR)</td>
<td>AstraZeneca</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate</td>
</tr>
<tr>
<td>empagliflozin (Jardiance®)</td>
<td>Boehringer Ingelheim</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</td>
</tr>
<tr>
<td>empagliflozin/metformin (Synjardy®)</td>
<td>Boehringer Ingelheim</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when both empagliflozin and metformin is appropriate</td>
</tr>
</tbody>
</table>

Agents in this review are not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

**OVERVIEW**

It is estimated that 29.1 million people in the United States have diabetes. Type 2 diabetes accounts for about 90% to 95% of all diagnosed cases of diabetes in adults. Improved glycemic control benefits patients with either type 1 or type 2 diabetes. In general, for every 1% reduction in hemoglobin A1c (HbA1c), the risk of developing microvascular diabetic complications (nephropathy, neuropathy, and retinopathy) is reduced by 40%.

In addition to exogenous insulin, there are several pathways by which blood glucose may be regulated in diabetic patients. The sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce renal glucose reabsorption in the proximal convoluted tubule, leading to increased urinary glucose excretion. There have been no clinical studies that have established conclusive evidence of a mortality risk reduction with these agents. The first study evaluating impact on macrovascular complications, (e.g., cardiovascular outcomes) associated with SGLT2 inhibitor therapy has been published. The EMPA-REG OUTCOME trial reported approximately a one-third relative risk reduction for cardiovascular death, hospitalization due to heart failure, and all-cause death with use of empagliflozin (Jardiance) as compared to placebo.

In 2016, the American Diabetes Association (ADA) Standards of Medical Care in Diabetes included the sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management algorithm for type 2 diabetes. The position statement recommends HbA1c < 7% as a reasonable target for most nonpregnant adult patients and < 7.5% in pediatric patients. A target HbA1c of 6% to 6.5% is recommended in most pregnant women. Metformin is recommended as initial therapy for the treatment of type 2 diabetes, along with lifestyle interventions at the time of diagnosis, unless metformin is contraindicated.
metformin fails to produce the target HbA1c after 3 months of therapy, a thiazolidinedione (TZD), sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitor, SGLT2 inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, or insulin should be added. In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or HbA1c, insulin therapy should be considered, with or without additional agents. If target HbA1c is still not achieved after an additional 3 months, then an agent from a different group listed should be added. Therapy should be individualized based on the needs, preferences, and tolerances of each patient. Patients with type 2 diabetes are at increased risk of cardiovascular morbidity and mortality; therefore, aggressive management of cardiovascular risk factors (e.g., blood pressure and lipid therapy, antiplatelet treatment, and smoking cessation) should be part of multifactorial risk reduction approach.\textsuperscript{12}

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) emphasize a comprehensive approach including individualized targets for weight loss, glucose, lipid, and hypertension management.\textsuperscript{13,14} The 2016 AACE/ACE treatment algorithm stratifies choice of therapy based on the patient’s initial HbA1c level: $< 7.5\%$, $\geq 7.5\%$, and $> 9\%$. The guidelines suggest patients with an HbA1c $< 7.5\%$ start with monotherapy, whereas patients with an HbA1c $\geq 7.5\%$ begin with dual therapy. Patients with an HbA1c $> 9\%$ and no symptoms may start on either dual or triple antihyperglycemic therapy; patients with an HbA1c $> 9\%$ with symptoms should begin insulin therapy, with or without other agents. The patient’s HbA1c should be reassessed every 3 months and failure to improve may warrant additional complementary therapy for optimal glycemic control. Within each therapy group (monotherapy, dual therapy, and triple therapy), the guidelines provide a hierarchical order of use for the drugs where, like the ADA guidelines, metformin is the preferred treatment of choice for monotherapy and first-line agent for dual and triple therapy. The AACE/ACE guidelines include the use of SGLT2 inhibitors as an alternative to metformin for monotherapy and as an appropriate add-on to metformin in dual therapy and triple therapy; agents for monotherapy are recommended in the following order (highest to lowest recommendation): metformin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, TZDs, alpha-glucosidase inhibitors, and sulfonylureas/secretagogue glinides. Notably, TZDs and sulfonylureas/secretagogue glinides should be used with caution.

The product empagliflozin/linagliptin (Glyxambi\textsuperscript{®}), which combines an SGLT2 inhibitor and a DPP-4 inhibitor, is not included in this clinical review.

**PHARMACOLOGY**\textsuperscript{15,16,17,18,19,20,21}

Canagliflozin (Invokana, Invokamet, Invokamet XR), dapagliflozin (Farxiga, Xigduo XR), and empagliflozin (Jardiance, Synjardy) are sodium-glucose cotransporter 2 (SGLT2) inhibitors. Sodium-glucose cotransporter 2, which is expressed in the proximal renal tubules, is the transporter responsible for the majority of the reabsorption of filtered glucose from the tubular lumen in the kidney. By inhibiting SGLT2, these agents reduce reabsorption of filtered glucose and lower the renal threshold for glucose (RTG), thereby increasing urinary glucose excretion and improving blood glucose control.

Metformin (Invokamet, Invokamet XR, Synjardy, Xigduo XR), a biguanide, decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Hypoglycemics, SGLT2 Inhibitors Review – September 2016

PHARMACOKINETICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Bioavailability (%)</th>
<th>Tmax (hr)</th>
<th>Half-life (hr)</th>
<th>Metabolism</th>
<th>Excretion (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>canagliflozin</td>
<td>65</td>
<td>1–2</td>
<td>10.6–13.1</td>
<td>hepatic (O-glucuronidation via UGT1A9 and 2B4; 2 inactive metabolites)</td>
<td>feces: 60</td>
</tr>
<tr>
<td>(Invokana)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>urine: 33</td>
</tr>
<tr>
<td>dapagliflozin</td>
<td>78</td>
<td>&lt; 2</td>
<td>12.9</td>
<td>hepatic (UGT1A9; 1 inactive metabolite)</td>
<td>feces: 21</td>
</tr>
<tr>
<td>(Farxiga)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>urine: 75</td>
</tr>
<tr>
<td>empagliflozin</td>
<td>nr</td>
<td>1.5</td>
<td>12.4</td>
<td>hepatic (O-glucuronidation via UGT1A3, 2B7,1A8, and 1A9)</td>
<td>feces: 41.2</td>
</tr>
<tr>
<td>(Jardiance)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>urine: 54.4</td>
</tr>
<tr>
<td>metformin</td>
<td>50–60</td>
<td>nr</td>
<td>6.2</td>
<td>no metabolites have been identified in humans</td>
<td>feces: nr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>urine: 90</td>
</tr>
</tbody>
</table>

The bioequivalence of canagliflozin/metformin (Invokamet/XR), dapagliflozin/metformin ER (Xigduo XR), and empagliflozin/metformin (Synjardy) combinations are bioequivalent to co-administration of corresponding doses of their individual components under fed conditions.

CONTRAINDICATIONS/WARNINGS

Canagliflozin (Invokana, Invokamet, Invokamet XR), dapagliflozin (Farxiga, Xigduo XR), and empagliflozin (Jardiance, Synjardy) are contraindicated in patients with a history of serious hypersensitivity reactions to the active ingredient. All SGLT2 inhibitors are contraindicated in patients with end stage renal disease (ESRD) and in patients receiving dialysis. The single component products are contraindicated in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² for canagliflozin, < 45 mL/min/1.73 m² for empagliflozin, and < 60 mL/min/1.73 m² for dapagliflozin. The combination products, canagliflozin/metformin (IR and ER) and empagliflozin/metformin, are contraindicated in patients with eGFR < 45 mL/min/1.73 m²; dapagliflozin/metformin ER is contraindicated in patients with serum creatinine ≥ 1.5 mg/dL in men and ≥ 1.4 mg/dL in women, or eGFR < 60 mL/min/1.73 m² or CrCl < 60 mL/min.

Hypersensitivity reactions, including anaphylaxis and angioedema, have occurred when using canagliflozin. If hypersensitivity reactions occur, canagliflozin should be discontinued and the patient should be treated as per standards of care and monitored until signs and symptoms resolve.

Metformin-containing products (Invokamet, Invokamet XR, Synjardy, Xigduo XR) are contraindicated in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis (DKA). The label carries a boxed warning that, although rare, potentially fatal lactic acidosis can occur due to metformin therapy. This risk increases with renal or hepatic impairment, sepsis, dehydration, excessive alcohol intake, and acute congestive heart failure.

In May 2015, the Food and Drug Administration (FDA) issued a warning that use of SGLT2 inhibitors may lead to ketoacidosis. Twenty cases of DKA, ketoacidosis, or ketosis were reported to the FDA in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014; all required emergency department visits or hospitalization. Diabetic ketoacidosis can occur in patients with diabetes, most commonly in patients with type 1 diabetes, and is usually accompanied by high serum glucose levels. The cases reported to the FDA were unusual because most of the patients had type 2 diabetes and their serum glucose levels, when reported, were only slightly increased unlike typical cases of DKA.
Healthcare providers and patients should monitor closely for signs of ketoacidosis, including difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness; if any occur, medical attention should be sought immediately. In December 2015, the FDA released a safety communication expanding their recommendation, advising that patients should stop taking their SGLT2 inhibitor and seek immediate medical attention if symptoms consistent with ketoacidosis occur. In addition, fatal cases of ketoacidosis have reported with use of SGLT2 inhibitors.

Combination agents containing metformin (Invokamet, Invokamet XR, Synjardy, Xigduo XR) carry boxed warnings regarding the risk of lactic acidosis which can occur with metformin accumulation. The risk increases with sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure. Treatment including metformin should be discontinued and the patient hospitalized immediately if lactic acidosis is suspected.

Long-term use of metformin may lead to vitamin B12 deficiency, which may be reversed with discontinuation of metformin or vitamin B12 supplementation. Monitor serum vitamin B12 every 2 to 3 years.

Patients with a history of genital mycotic infections and uncircumcised males are more likely to develop mycotic infections when using SGLT2 inhibitors and should be monitored closely. Patients treated with SGLT2 inhibitors are also at increased risk for urinary tract infections and should be monitored closely. As part of the December 2015 FDA safety communication, patients are advised they should be aware of signs and symptoms of urinary tract infection and contact their health care professional if experienced.

SGLT2 inhibitors can lead to renal impairment. There have been reports of acute kidney injury, some requiring hospitalization and dialysis in patients treated with use of canagliflozin- and dapagliflozin-containing agents.

Symptomatic hypotension can occur after starting SGLT2 inhibitors as they cause osmotic diuresis leading to intravascular volume contraction. Symptomatic hypotension occurs particularly in patients with impaired renal function (eGFR < 60 mL/min/1.73 m²), elderly patients, patients with low systolic blood pressure, and patients on diuretics or drugs which interfere with the renin-angiotensin-aldosterone system. The patient’s volume status should be assessed and corrected prior to starting SGLT2 inhibitor therapy and monitored thereafter.

SGLT2 inhibitors can decrease the eGFR and increase serum creatinine. Patients with hypovolemia, particularly the elderly and those with moderate renal impairment, may be at an increased risk for these changes. Renal function should be evaluated prior to initiation and monitored periodically thereafter.

Canagliflozin can cause hyperkalemia. Patients with moderate renal impairment who are also taking medications that interfere with potassium excretion or the renin-angiotensin-aldosterone system are more susceptible to the development of hyperkalemia. Potassium levels should be monitored regularly after beginning canagliflozin in patients with impaired renal function and in patients who are predisposed to increased potassium levels due to mediations or other medical conditions.

SGLT2 inhibitors can increase the risk of hypoglycemia when combined with insulin or insulin secretagogues; therefore, a lower dose of insulin or insulin secretagogue may be required when given in combination with a SGLT2 inhibitor.
SGLT2 inhibitors may cause dose-related increases in low-density-lipoprotein cholesterol (LDL-C); therefore, monitoring is warranted to determine the need for treatment intervention.

The incidence of bladder cancer reported in clinical trials was 0.17% in patients treated with dapagliflozin compared with a 0.03% incidence in the placebo arm. Bladder cancer risk factors were equally balanced between the two groups at baseline. After excluding patients who had less than a 1-year exposure to dapagliflozin at time of bladder cancer diagnosis, there were 4 cases in the dapagliflozin arms and no cases in the placebo arms of these trials. At this time, there are insufficient data to determine whether dapagliflozin has an effect on pre-existing bladder tumors. Dapagliflozin should not be used in patients with active bladder cancer or a prior history of bladder cancer. To date, increased risk of bladder cancer has not been reported with products containing canagliflozin (Invokamet, Invokana) or empagliflozin (Jardiance, Synjardy).

Temporarily discontinue canagliflozin/metformin, canagliflozin/metformin XR, dapagliflozin/metformin ER, and empagliflozin/metformin in patients undergoing radiologic procedures who receive intravenous iodinated contrast agents and in patients undergoing any surgical procedure associated with restricted intake of food and fluids. Caution should be used with metformin-containing products in patients experiencing hypoxic states.

In September 2015, the FDA issued a safety communication regarding decreased bone mineral density and increased risk of bone fracture associated with canagliflozin use. Fractures have been reported as early as 12 weeks after starting canagliflozin therapy. Pooled clinical trial data report an incidence of bone fracture of 17.7 for canagliflozin 300mg compared to 14.2 for comparator per 1,000 patient years of exposure; mean duration of exposure was 68 weeks. Prescribers should consider all factors that may contribute to fracture risk before initiating canagliflozin. The FDA is evaluating this risk with dapagliflozin- and empagliflozin-containing products. In clinical studies, 13 patients with moderate renal impairment who were treated with dapagliflozin experienced bone fracture, the majority of which were reported within the first 52 weeks of therapy, compared to no patients treated with placebo.

In May 2016, the FDA issued another safety communication in May 2016 regarding interim safety findings from an ongoing clinical trial, the Canagliflozin Cardiovascular Assessment Study (CANVAS). The interim findings indicate an increase in leg and foot amputations (primarily toes) in patients treated with canagliflozin compared to placebo with an average duration of therapy of 4.5 years. Although a causal relationship has not been found, the FDA advises healthcare professionals to monitor for signs and symptoms of any new pain/tenderness, sores/ulcers, or infections in patients' legs and/or feet and to encourage patients to report any symptoms.

**DRUG INTERACTIONS**

When administered with UDP-glucuronosyltransferase (UGT) enzyme inducers (e.g., rifampin, phenytoin, ritonavir, phenobarbital), the exposure of canagliflozin (Invokana, Invokamet, Invokamet XR) is reduced, which may decrease the efficacy of canagliflozin. If co-administration is needed and the patient has an eGFR > 60 mL/min/1.73 m², prescribers should consider increasing the dose from 100 mg to 300 mg once daily, if tolerated. Other antihyperglycemic therapy should be considered in patients with an eGFR of 45 to 59 mL/min/1.73 m² who are also taking an UGT inducer and require additional glycemic control. Empagliflozin (Jardiance, Synjardy) does not inhibit UGT1A1; therefore, no drug interaction is expected when co-administered with substrates of this enzyme. Although
metabolism of dapagliflozin (Farxiga, Xigduo XR) involves UGT enzymes, current labeling does not report drug interactions with concurrent use of UGT enzyme inducers.

Co-administration of digoxin and canagliflozin may increase the exposure to digoxin and, therefore, close monitoring and dose adjustment of either agent, if needed, is warranted.

Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and the dapagliflozin 3-O-glucuronide metabolite is a substrate for the OAT3 active transporter. Dapagliflozin has not been shown to induce nor inhibit any of the cytochrome isoenzymes or P-gp, OCT2, OAT1, or OAT3 active transporters. None of the co-administered drugs that were studied (including other classes of oral antidiabetic medications or rifampin) have demonstrated the need for dosage adjustment when given concomitantly with dapagliflozin. Empagliflozin is a substrate for uptake transporters P-gp, OAT3, OATP1B1, and OATP1B3, but does not inhibit these transporters at clinically relevant plasma concentrations; therefore, no relevant drug interactions are expected.

Cationic drugs, such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin that are eliminated by renal tubular secretion have a theoretical potential interaction with metformin by competing for common renal tubular transport systems. No specific dosing changes are recommended. Increased metformin plasma concentrations are seen with concurrent administration of cimetidine, furosemide, and nifedipine. No specific dosing changes are recommended. Contrast agents increase the risk of metformin-induced lactic acidosis. Concomitant use of topiramate or other carbonic anhydrase inhibitors may increase the risk of lactic acidosis. Monitor for signs and symptoms of acidosis when these drugs are used concomitantly with metformin-containing agents (Invokamet, Invokamet XR, Synjardy, Xigduo XR).
## Adverse Effects

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Drug</th>
<th>canagliflozin (Invokana)</th>
<th>dapagliflozin (Farxiga)</th>
<th>empagliflozin (Jardiance)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genital mycosis, female</td>
<td></td>
<td>10.4-11.4 (3.2)</td>
<td>6.9-8.4 (1.5)</td>
<td>5.4-6.4 (1.5)</td>
</tr>
<tr>
<td>Genital mycosis, male</td>
<td></td>
<td>3.7-4.2 (0.6)</td>
<td>2.7-2.8 (0.3)</td>
<td>1.6-3.1 (0.4)</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td></td>
<td>4.3-5.9 (4)</td>
<td>4.3-5.7 (3.7)</td>
<td>7.6-9.3 (7.6)</td>
</tr>
<tr>
<td>Increased Urination</td>
<td></td>
<td>4.6-5.3 (0.8)</td>
<td>2.9-3.8 (1.7)</td>
<td>3.2-3.4 (1)</td>
</tr>
<tr>
<td>Vulvovaginal pruritus</td>
<td></td>
<td>1.6-3 (0)</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>Thirst</td>
<td></td>
<td>2.3-2.8 (0.2)</td>
<td>nr</td>
<td>1.5-1.7 (0)</td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
<td>1.8-2.3 (0.9)</td>
<td>1.9-2.2 (1.5)</td>
<td>nr</td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
<td>2.2-2.3 (1.5)</td>
<td>2.5-2.8 (2.4)</td>
<td>1.1-2.3 (1.4)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td></td>
<td>nr</td>
<td>6.3-6.6 (6.2)</td>
<td>nr (Jardiance); reported (Synjardy)</td>
</tr>
<tr>
<td>Back Pain</td>
<td></td>
<td>nr</td>
<td>3.1-4.2 (3.2)</td>
<td>reported</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td>nr</td>
<td>2.3-2.7 (2.3)</td>
<td>nr</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td></td>
<td>nr</td>
<td>2.1-2.5 (1.5)</td>
<td>2.9-3.9 (3.4)</td>
</tr>
<tr>
<td>Discomfort with urination</td>
<td></td>
<td>nr</td>
<td>1.6-2.1 (0.7)</td>
<td>nr</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td></td>
<td>nr</td>
<td>1.7-2 (1.4)</td>
<td>nr</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. Incidences for the placebo group are indicated in parentheses. nr = not reported.

When used alone, SGLT2 inhibitors do not appear to cause hypoglycemia. Use of SGLT2 inhibitors results in modest weight loss.

As communicated by the FDA, urine glucose tests should not be used to monitor glycemic control in patients that are on SGLT2 inhibitors. Sodium-glucose cotransporter 2 inhibitors increase urinary glucose excretion and will result in positive urine glucose tests. In addition, measurement of 1,5-anhydroglucitol (1,5-AG), a glucose analog that competes with glucose for renal reabsorption, is an unreliable method to assess glycemic control.

Initiation of metformin therapy is commonly associated with gastrointestinal adverse effects. As described above, long-term use of metformin may lead to vitamin B12 deficiency.
SPECIAL POPULATIONS

Pediatrics

The safety and efficacy of SGLT2 inhibitors have not been determined in patients under 18 years old.

Geriatrics

No dosage adjustment is recommended for canagliflozin, dapagliflozin, or empagliflozin based on age. Patients 65 years and older may be at increased risk of experiencing intravascular volume-depletion adverse reactions compared to younger patients while on SGLT2 inhibitor therapy; for canagliflozin, this may occur particularly with the 300 mg dose and a more prominent increase in incidence was seen in patients who were 75 years and older. Studies with empagliflozin reported increased risk of urinary tract infections in those 75 years of age and older. When comparing younger patients to older patients, the older patients experienced smaller reductions in HbA1c relative to placebo.

Although differences in responses between elderly and younger patients are not expected, controlled studies of metformin did not include sufficient numbers of elderly patients. Due to the age-related decline of renal function, initiation and maintenance dosing of metformin should be based on a conservative approach in patients with advanced age.

Pregnancy

Agents in this class review are Pregnancy Category C (e.g. there are no adequate and well-controlled studies of in pregnant women.), with the exception of canagliflozin-containing products. Canagliflozin (Invokana) and canagliflozin/metformin (Invokamet) were previously assigned Pregnancy Category C, but their labeling has been updated to descriptive information based on the Pregnancy and Lactation Labeling Rule (PLLR). Canagliflozin/metformin ER (Invokamet XR) was not assigned a pregnancy category and also contains descriptive information.

There is insufficient data for use of SGLT2 inhibitors in pregnant women to determine associated risks. Animal studies report affects on renal development associated with use of agents. Based on animal studies, canagliflozin is not recommended for use during the second and third trimesters of pregnancy; product labels for dapagliflozin and empagliflozin recommend use during pregnancy only if the potential benefit justifies the potential risks to the fetus, particularly during the second and third trimesters.

Renal Impairment

The safety and efficacy of SGLT2 inhibitors have not been studied in patients with severe renal impairment, end stage renal disease (ESRD), and in patients on dialysis. These agents are not expected to be effective in these patient populations. Clinical studies have shown that the glucose lowering benefit of SGLT2 inhibitors decreases in patients with worsening renal function. Also, the risks of renal impairment, volume depletion adverse reactions, and urinary tract infection-related adverse reactions may increase with worsening renal function.

The risk of metformin accumulation and lactic acidosis also increases with worsening renal impairment. However in April 2016, the FDA published an alert stating that based on evaluation of various safety
studies regarding metformin, they have concluded that metformin may be safely used in patients with mild renal impairment and some patients with moderate renal impairment.64

Canagliflozin (Invokana) is contraindicated in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² and its use should be discontinued if eGFR persistently falls below 45 mL/min/1.73m².

Dapagliflozin (Farxiga) is contraindicated in patients with eGFR < 60 mL/min/1.73 m².

Canagliflozin/metformin (Invokamet, Invokamet XR) and empagliflozin/metformin (Synjardy) are contraindicated in patients with serum creatinine ≥ 1.5 mg/dL in men and ≥ 1.4 mg/dL in women, or eGFR < 45 mL/min/1.73 m². Also, the dose of canagliflozin/metformin should be limited to 50 mg twice daily in those with eGFR 45 to less than 60 mL/min/1.73 m², and the dose of canagliflozin/metformin ER should be limited to 100 mg/day in those with eGFR 45 to less than 60 mL/min/1.73 m².

Dapagliflozin/metformin (Xigduo XR) is contraindicated in men with serum creatinine ≥ 1.5 mg/dL and ≥1.4 mg/dL in women, or eGFR < 60 mL/min/1.73 m², or creatinine clearance (CrCl) < 60 mL/min. Empagliflozin/metformin (Synjardy) is contraindicated in patients with serum creatinine ≥ 1.5 mg/dL in men and ≥ 1.4 mg/dL in women, or eGFR < 45 mL/min/1.73 m².

Hepatic Impairment

Canagliflozin (Invokana) is not recommended for use in patients with severe hepatic impairment. No dosage adjustments are recommended for those with mild or moderate hepatic impairment. Use of canagliflozin/metformin (Invokamet, Invokamet XR) is not recommended in patients with hepatic impairment.

No dose adjustment is recommended for dapagliflozin and empagliflozin for patients with hepatic impairment. However, the safety and efficacy of these agents have not been specifically studied in patients with severe hepatic impairment.

In general, the metformin-containing products canagliflozin/metformin, dapagliflozin/metformin ER, and empagliflozin/metformin are not recommended in patients with hepatic impairment due to increased risk of lactic acidosis.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Parameters</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>canagliflozin</td>
<td>Recommended starting dose</td>
<td>100 mg once daily taken before the first meal</td>
<td>100, 300 mg tablet</td>
</tr>
<tr>
<td>(Invokana)</td>
<td>Patients tolerating canagliflozin 100 mg daily, requiring additional</td>
<td>300 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glycemic control, and have an eGFR ≥ 60 mL/min/1.73 m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate renal impairment (eGFR 45 to 59 mL/min/1.73 m²)</td>
<td>100 mg once daily</td>
<td></td>
</tr>
<tr>
<td>canagliflozin/</td>
<td>Recommended starting dose</td>
<td>For patients on metformin: switch to Invokamet containing canagliflozin</td>
<td>50/500, 50/1,000, 150/500, 150</td>
</tr>
<tr>
<td>metformin (Invokamet)</td>
<td></td>
<td>50 mg twice daily of the canagliflozin component</td>
<td>mg/1,000 mg immediate-release</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For patients on canagliflozin: switch to Invokamet containing</td>
<td>release tablet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>metformin 500 mg with a similar total daily dose of canagliflozin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>taken twice daily with meals</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For patients on canagliflozin and metformin: switch to Invokamet</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>containing the same total daily doses of each component</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>taken twice daily with meals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate renal impairment (eGFR 45 to 59 mL/min/1.73 m²)</td>
<td>100 mg/day of the canagliflozin component</td>
<td></td>
</tr>
<tr>
<td>canagliflozin/</td>
<td>Recommended starting dose</td>
<td>Base initial dose on patient’s current regimen</td>
<td>50/500, 50/1,000, 150/500, 150</td>
</tr>
<tr>
<td>metformin ER</td>
<td></td>
<td>For patients not on either metformin or</td>
<td>mg/1,000 mg extended-release</td>
</tr>
<tr>
<td>(Invokamet XR)</td>
<td></td>
<td>canagliflozin: two 50/500 mg tablets once daily with the morning meal</td>
<td>tablet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For patients on metformin: switch to 2 tablets of Invokamet XR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>containing a total of canagliflozin 100 mg with a similar total</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>daily dose of metformin taken once daily with the morning meal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For patients on canagliflozin: switch to 2 tablets of Invokamet XR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>containing a total of metformin 1,000 mg with the current total</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>daily dose of canagliflozin taken once daily with the morning meal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For patients on canagliflozin and metformin: switch to 2 tablets of</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Invokamet XR containing the same total daily doses of each component</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>taken once daily with the morning meal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate renal impairment (eGFR 45 to 59 mL/min/1.73 m²)</td>
<td>100 mg/day of the canagliflozin component</td>
<td></td>
</tr>
<tr>
<td>dapagliflozin</td>
<td>Recommended starting dose</td>
<td>5 mg once daily, taken in the morning, with or without food</td>
<td>5, 10 mg tablet</td>
</tr>
<tr>
<td>(Farxiga)</td>
<td></td>
<td>Patients tolerating dapagliflozin 5 mg once daily who require</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>additional glycemic control</td>
<td></td>
</tr>
</tbody>
</table>

**eGFR** = estimated glomerular filtrate rate
Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Parameters</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>dapagliflozin/metformin ER (Xigduo XR)</td>
<td>Recommended starting dose</td>
<td>Once daily, taken in the morning with food; Gradually escalate dosage to reduce gastrointestinal side effects due to metformin; Do not exceed 10 mg dapagliflozin/1,000 mg metformin XR per day; Swallow whole; do not crush, cut, or chew</td>
<td>5/500, 50/1,000, 10/500, 10/1,000 mg extended-release tablet</td>
</tr>
<tr>
<td>empagliflozin (Jardiance)</td>
<td>Recommended starting dose</td>
<td>10 mg once daily in the morning, with or without food</td>
<td>10, 25 mg tablet</td>
</tr>
<tr>
<td></td>
<td>Patients tolerating empagliflozin 10 mg once daily who require additional glycemic control</td>
<td>25 mg once daily</td>
<td></td>
</tr>
<tr>
<td>empagliflozin/metformin (Synjardy)</td>
<td>Recommended starting dose in patients on metformin</td>
<td>Twice daily with meals; empagliflozin 5 mg with similar total daily dose of metformin</td>
<td>5/500, 5/1,000, 12.5/500, 12.5/1,000 mg immediate-release tablet</td>
</tr>
<tr>
<td></td>
<td>Recommended starting dose in patients on empagliflozin</td>
<td>Twice daily with meals; metformin 500 mg with similar total daily dose of empagliflozin; Gradually escalate dosage to reduce gastrointestinal side effects due to metformin; Do not exceed 12.5 mg empagliflozin/1,000 mg metformin per day</td>
<td></td>
</tr>
</tbody>
</table>

eGFR = estimated glomerular filtrate rate

Renal function should be assessed prior to starting SGLT-2 inhibitor therapy. Do not initiate canagliflozin if eGFR < 30 mL/min/1.73m²; canagliflozin/metformin, empagliflozin or empagliflozin/metformin if eGFR < 45 mL/min/1.73 m²; and dapagliflozin or dapagliflozin/metformin if eGFR < 60 mL/min/1.73 m². Do not initiate any of the metformin-containing medications in patients with serum creatinine levels ≥ 1.5 mg/dL for males or 1.4 mg/dL for females or eGFR < 45 mL/min/1.73 m². Discontinue SGLT2 inhibitor therapy if eGFR persistently falls below these respective eGFR levels.

In patients with an eGFR of 45 to less than 60 mL/min/1.73m², the total daily dose of canagliflozin dosage should be limited to 100 mg, as 100 mg once daily dose for canagliflozin and 50 mg twice daily for canagliflozin/metformin.

**CLINICAL TRIALS**

Search Strategies

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the use of all brand names in this class. Randomized, comparative, controlled trials performed in the United States comparing agents within this class in an outpatient setting for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Using these criteria, numerous
studies were found. Data were further excluded based on the following characteristics: formulation or drug not available in U.S., single-blind or open-label design, or single-dose study. Despite some inherent bias found in all studies, including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance.

Due to a paucity of double-blind, direct comparator trials, studies with a placebo comparator were included in the absence of comparative trials.

There have been no clinical efficacy studies conducted with the combination products canagliflozin/metformin (Invokamet, Invokamet XR), dapagliflozin/metformin ER (Xigduo XR), and empagliflozin/metformin (Synjardy). Bioequivalence of the combination product to respective the SGLT2 inhibitor and metformin co-administered as individual tablets has been demonstrated in healthy subjects.

Since 2008, the FDA requires large studies that assess the cardiovascular risk of new antidiabetic agents. These studies (1) should use an upper bound of 95% confidence interval of < 1.3 for the risk ratio of important CV events; (2) must include patients with relatively advanced disease, elderly, and those with renal impairment; (3) must include a minimum of 2 years safety data; (4) must include prospective data with independent adjudication of CV events in all phase 2 and 3 studies; and (5) may include meta-analyses of CV events. Cardiovascular outcomes studied will be included in this review when available for the drugs in this class.

**canagliflozin (Invokana) monotherapy**

A 26-week double-blind, placebo-controlled study was performed in 584 patients with type 2 diabetes who were not controlled by diet and exercise in order to determine the safety and efficacy of canagliflozin. Patients who were taking other antihyperglycemics (n=281) discontinued the medication and entered an 8-week washout period followed by a 2-week, single-blind, placebo run-in period. Patients who were not taking oral antihyperglycemics (n=303) were allowed to enter the 2-week, single-blind, placebo run-in period immediately. After the placebo run-in period, patients were then randomized to receive canagliflozin 100 mg, canagliflozin 300 mg, or placebo once daily. Primary endpoint was the change from baseline in HbA1c. At week 26, HbA1c was significantly reduced from baseline with canagliflozin 100 and 300 mg compared with placebo (-0.77, -1.03 and 0.14%, respectively; p<0.001 for both dosages). The percent of patients achieving an HbA1c < 7% was 45%, 62%, and 21% for patients treated with canagliflozin 100 mg, canagliflozin 300 mg, and placebo once daily, respectively (p<0.001). Canagliflozin 100 mg and 300 mg once daily also improved fasting plasma glucose (FPG) compared to placebo (-27, -35, and 8 mg/dL, respectively). Patients treated with canagliflozin 100 mg and 300 mg once daily also had greater reductions in the 2-hour postprandial glucose (PPG) compared to placebo (-43, -59, and 5 mg/dL, respectively) and significant reductions in body weight compared to placebo (-2.8%, -3.9%, and -0.6%, respectively; p<0.001 for both). Statistically significant changes in systolic blood pressure were also observed for 100 mg and 300 mg dosages (-3.7 mmHg and -5.4 mmHg, respectively; p<0.001).
canagliflozin add-on therapy to metformin

A double-blind, placebo- and active-controlled study was performed in 1,284 patients with type 2 diabetes who were inadequately controlled on metformin monotherapy (≥ 2,000 mg/day, or ≥ 1,500 mg/day if higher dose not tolerated) to assess the safety and efficacy of canagliflozin when combined with metformin.\textsuperscript{75,76} If patients were taking less than the required metformin dose or were taking metformin plus another antihyperglycemic (n=275), they were switched to metformin monotherapy for at least 8 weeks before they were allowed to enter the 2-week, single-blind, placebo run-in. Patients who were already taking the required metformin dose (n=1,009) were immediately allowed to enter a 2-week, single-blind, placebo run-in period. After completing the placebo run-in phase, patients were randomized to receive canagliflozin 100 mg, canagliflozin 300 mg, or placebo once daily with metformin for 26 weeks (Period I). Patients who completed Period I then entered Period II for an additional 26 weeks during which those who were initially received placebo switched to sitagliptin 100 mg in a blinded fashion, while the other patients in the study continued their original study drug. Comparisons were performed for canagliflozin versus placebo at week 26 and canagliflozin versus sitagliptin at week 52. At week 26, the study indicated that the addition of canagliflozin 100 mg and 300 mg resulted in statistically significant improvements in HbA1c compared to placebo with metformin (-0.79%, -0.94% and -0.17%, respectively; p<0.001 for both dosages). The percent of patients achieving an HbA1c < 7% was 58%, 46%, and 30% with the addition of canagliflozin 300 mg and 100 mg, and placebo, respectively. A larger reduction in FPG occurred with canagliflozin 100 mg (-27 mg/dL) and canagliflozin 300 mg (-38 mg/dL) compared to placebo (2 mg/dL). A reduction in PPG was also greater with canagliflozin 100 mg (-48 mg/dL) and canagliflozin 300 mg (-57 mg/dL) compared to placebo (-10 mg/dL). Patients treated with canagliflozin 100 mg and 300 mg once daily also had greater reductions in body weight compared to placebo (-3.7%, -4.2%, and -1.2%, respectively; p<0.001 for both dosages). At week 52, canagliflozin 100 mg and 300 mg demonstrated non-inferiority, and canagliflozin 300 mg demonstrated statistical superiority, to sitagliptin in lowering HbA1c (-0.73%, –0.88%,–0.73%, respectively). Canagliflozin 100 mg and 300 mg reduced body weight compared to sitagliptin at week-52 (-3.8%, -4.2%, and -1.3%, respectively; p<0.001). Incidence of hypoglycemia was higher with canagliflozin; 6.8% with both canagliflozin doses compared to 4.1% with sitagliptin and 2.7% with placebo/sitagliptin at during 52 weeks. Statistically significant mean changes in systolic blood pressure relative to placebo were observed with canagliflozin 100 mg and 300 mg (-5.4 mmHg and -6.6 mmHg, respectively; p<0.001 for both doses).

The safety and efficacy of canagliflozin in combination with metformin were studied in 1,450 patients with type 2 diabetes who were inadequately controlled on metformin monotherapy (≥ 2,000 mg/day, or ≥ 1,500 mg/day if higher dose not tolerated) in a 52-week, double-blind, active-controlled study.\textsuperscript{77} After a 2-week, single-blind, placebo run-in period, patients who were already taking the maximum required metformin dose (n=928) were randomized. Other patients (n=522) were switched to metformin monotherapy for 10 weeks and then entered the 2-week single-blind run-in period. After the 2-week run-in period, patients were randomized to receive canagliflozin 100 mg or 300 mg, or glimepiride (titration up to 6 mg or 8 mg) given once daily with metformin. The study concluded that addition of canagliflozin 100 mg and glimepiride had similar reductions in Hba1c; only canagliflozin 300 mg plus metformin provided a greater reduction from baseline in the HbA1c level when compared to glimepiride plus metformin (difference -0.12%; 95% confidence interval [CI], -0.22 to -0.02). The percent of patients reaching an HbA1c < 7% was 54%, 60%, and 56% for patients treated with canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride, respectively. A larger reduction in FPG
occurred in the canagliflozin 100 mg (-24 mg/dL) and canagliflozin 300 mg (-28 mg/dL) compared to glimepiride (-18 mg/dL). Patients in the canagliflozin 100 mg and 300 mg groups also had greater reductions in body weight compared to the glimepiride group (-4.2%, -4.7%, and +1%, respectively; p<0.001 for both).

canagliflozin add-on therapy to sulfonylurea

An 18-week, double-blind, placebo-controlled sub-study was performed in 127 patients with type 2 diabetes who were inadequately controlled on sulfonylurea monotherapy in order to assess the safety and efficacy of canagliflozin combined with sulfonylurea.\textsuperscript{78} Patients taking sulfonylurea monotherapy and who were stable on a protocol specified dose (≥ 50% maximum dose) for at least 10 weeks completed a 2-week, single-blind, placebo run-in phase. Upon completion of the run-in phase, patients with poor glycemic control were randomized to add-on therapy with canagliflozin 100 mg, canagliflozin 300 mg, or placebo once daily. The study concluded that canagliflozin 100 mg and 300 mg daily resulted in statistically significant improvements in HbA1c compared to placebo when combined with a sulfonylurea (p<0.001). Canagliflozin 300 mg daily compared to placebo also resulted in higher rates of achieving an HbA1c < 7% (33% versus 5%) and larger reductions in FPG (-36 mg/dL versus +12 mg/dL).

canagliflozin add-on therapy to metformin and sulfonylurea

The efficacy and safety of canagliflozin in combination with metformin and a sulfonylurea were studied in 469 patients with type 2 diabetes who were inadequately controlled on combined metformin (≥ 2,000 mg/day, or ≥ 1,500 mg/day if higher dose not tolerated) and sulfonylurea (maximum or near maximum dose) therapy in a 26-week, double-blind, placebo-controlled study.\textsuperscript{79} Patients who were on protocol-specified doses of metformin and sulfonylurea (n=372) were allowed to directly enter a 2-week, single-blind, placebo run-in period. Other patients (n=97) were required to be on a stable protocol dose of metformin and sulfonylurea for 8 weeks or more before entering the 2-week run-in phase. After the run-in period, patients were randomized to receive canagliflozin 100 mg or 300 mg, or placebo taken once daily added to metformin and sulfonylurea. The study resulted in canagliflozin 100 mg and 300 mg having statistically significant improvements in HbA1c compared to placebo when combined with metformin and sulfonylurea (p<0.001). More patients treated with canagliflozin 100 mg or 300 mg obtained an HbA1c < 7% (43% and 57%, respectively) compared to placebo (18%) (p<0.001). Canagliflozin 100 mg and 300 mg lowered FPG (-18 mg/dL and -31 mg/dL, respectively) more than placebo (4 mg/dL). Patients in the canagliflozin 100 mg and 300 mg groups also had greater reductions in body weight compared to the placebo group (-2.1%, -2.6%, and -0.7%, respectively; p<0.001 for both).

A 52-week, double blind, active-controlled study enrolled 755 patients with type 2 diabetes who were uncontrolled on a combination of metformin (≥ 2,000 mg/day, or ≥ 1,500 mg/day, if higher dose not tolerated) and sulfonylurea (maximum or near maximum dose) was performed to compare the efficacy and safety of the addition of canagliflozin 300 mg versus sitagliptin 100 mg to metformin and sulfonylurea.\textsuperscript{80,81} Patients already on the protocol-specified doses of metformin and sulfonylurea (n=716) were allowed to enter a 2-week single-blind, placebo run-in phase. Other patients (n=39) had to be stabilized on the protocol-specified dose of metformin and sulfonylurea for at least 8 weeks before entering the 2-week run-in period. All patients were then randomized to canagliflozin 300 mg or sitagliptin 100 mg plus metformin and sulfonylurea. A total of 464 patients completed the 52-week treatment period. At the conclusion of the study, it was determined that canagliflozin 300 mg resulted in a greater HbA1c reduction compared to sitagliptin 100 mg when added to metformin and
sulfonylurea (p<0.05). The rate of patients achieving an HbA1c < 7% was higher in the canagliflozin 300 mg treatment group (48%) versus the sitagliptin 100 mg treatment group (35%). The addition of canagliflozin 300 mg also lowered FPG more than sitagliptin 100 mg (-30 and -6 mg/dL, respectively). Patients in the canagliflozin 300 mg group also had greater reductions in body weight compared to the sitagliptin group (-2.5% and -0.3%, respectively; p<0.001). A decrease in systolic blood pressure was seen with canagliflozin 300 mg, while a small increase was reported with sitagliptin 100 mg (+5.06 mmHg versus +0.85 mmHg).

**canagliflozin add on therapy to metformin and pioglitazone**

A 26-week, double-blind, placebo-controlled study was performed in 342 patients with type 2 diabetes who were poorly controlled on metformin (≥ 2,000 mg/day, or ≥ 1,500 mg/day, if higher dose not tolerated) and pioglitazone (30 or 45 mg/day) to evaluate the efficacy and safety of canagliflozin plus metformin and pioglitazone. Patients (n=163) who were already on protocol-specific doses of metformin and pioglitazone entered a 2-week, single-blind, placebo run-in period. Other patients (n=181) were required to be on metformin and pioglitazone at protocol-specific stable doses for at least 8 weeks before entering the 2-week run-in period. After the run-in phase, patients were then randomized to canagliflozin 100 mg or 300 mg, or placebo given once daily with metformin and pioglitazone. The study resulted in the addition of canagliflozin 100 mg and 300 mg having statistically significant improvements in HbA1c compared to placebo (p<0.001). Canagliflozin 100 mg and 300 mg resulted in a greater percentage of patients achieving an HbA1c < 7% compared to placebo (47, 64, and 33%, respectively) (p<0.001). Canagliflozin 100 mg and 300 mg had larger reductions in FPG (-27 and -33 mg/dL, respectively) compared to placebo (3 mg/dL). Patients in the canagliflozin 100 mg and 300 mg groups also had greater reductions in body weight compared to placebo when added to metformin and pioglitazone (-2.8%, -3.8% and -0.1%, respectively; p<0.001). In addition, statistically significant mean changes from baseline in systolic blood pressure relative to placebo were -4.1 mmHg and -3.5 mmHg with canagliflozin 100 mg and 300 mg, respectively (p<0.05 for both doses).

**canagliflozin add on therapy to insulin**

An 18-week, double-blind, placebo-controlled substudy of a cardiovascular study was performed to assess the efficacy and safety of canagliflozin in combination with insulin. The study included 1,718 patients with type 2 diabetes who were uncontrolled on insulin at doses of at least 30 units/day or who were on insulin in combination with other antihyperglycemic agents. Patients entered a 2-week, single-blind, placebo run-in period after at least 10 weeks of basal, bolus, or basal/bolus insulin therapy. After the run-in period, patients were randomized to receive canagliflozin 100 mg or 300 mg, or placebo once daily plus insulin. The study concluded that canagliflozin-treated patients experienced a statistically significant improvement in their HbA1c levels (p<0.001) compared to placebo treated patients when added to insulin. The percent of patients’ achieving an HbA1c < 7% was 20%, 25%, and 8% for canagliflozin 100 mg, canagliflozin 300 mg, and placebo, respectively. Canagliflozin 100 mg and 300 mg also resulted in a larger decrease in FPG (-19 and -25 mg/dL, respectively) compared to placebo (4 mg/dL). Patients in the canagliflozin 100 mg and 300 mg groups also had greater reductions in body weight compared to the placebo group (-1.8%, -2.8%, and -0.1%, respectively; p<0.001). Statistically significant mean change in systolic blood pressure relative to placebo was reported with both doses of canagliflozin; -3.5 mmHg for the 100 mg dose (p=0.023) and -6 mmHg for the 300 mg dose (p<0.001).
**dapagliflozin (Farxiga) monotherapy**

Dapagliflozin was studied as monotherapy in treatment-naïve patients with type 2 diabetes. A 24-week randomized, double-blind, placebo-controlled phase 3 trial (n=485) randomly assigned patients to 1 of 7 arms to receive once-daily placebo or dapagliflozin 2.5 mg, 5 mg, or 10 mg once daily in the morning (main cohort) or evening (exploratory cohort). The primary endpoint was change in baseline HbA1c in the main cohort. At 24 weeks, the adjusted mean HbA1c reductions from baseline were -0.58 for dapagliflozin 2.5 mg, -0.77 for dapagliflozin 5 mg, and -0.89 for dapagliflozin 10 mg compared to -0.2 for placebo. These reductions were statistically significant with 5 mg and 10 mg dapagliflozin (p=0.0005 and p<0.0001, respectively). An increased incidence in signs and symptoms and other reports suggestive of urinary tract infections (UTIs) and genital infections were noted with dapagliflozin treatment.

**dapagliflozin initial combination therapy with metformin extended-release (Xigduo XR)**

A total of 1,241 treatment-naïve patients with inadequately controlled type 2 diabetes (HbA1c >7.5 % and <12%) participated in 2 active-controlled studies of 24-week duration to evaluate the safety and efficacy of initial therapy with dapagliflozin, metformin extended-release, or the combination. Patients were randomized in a double-blind fashion to 1 of 3 treatment arms: a combination of dapagliflozin and metformin ER or monotherapy with either dapagliflozin or metformin ER. In the first trial, dapagliflozin was dosed at 5 mg daily and, in the second trial, dapagliflozin was dosed at 10 mg daily. Metformin ER in combination and as monotherapy was titrated to 2,000 mg per day. The primary endpoint was HbA1c change from baseline; secondary endpoints included change in fasting plasma glucose (FPG) and weight. In both trials, combination therapy led to significantly greater reductions in HbA1c compared with either monotherapy. In study 1, HbA1c reductions were -2.05 for dapagliflozin plus metformin ER, -1.19 for dapagliflozin, and -1.35 for metformin ER (p<0.0001). In study 2, HbA1c reductions were -1.98 for dapagliflozin + metformin ER, -1.45 for dapagliflozin, and -1.44 for metformin ER (p<0.0001). Single agent dapagliflozin 10 mg was non-inferior to single agent metformin ER for reducing HgA1c in this study. Combination therapy was also statistically superior to monotherapy with either agent in reduction of FPG (p<0.0001 for both studies); combination therapy was more effective than metformin ER for weight reduction (p<0.0001). Events suggestive of genital infection were reported in 6.7%, 6.9%, and 2% (study 1) and 8.5%, 12.8%, and 2.4% (study 2) of patients in combination, dapagliflozin, and metformin ER groups, respectively; events suggestive of UTIs were reported in 7.7%, 7.9%, and 7.5% (study 1) and 7.6%, 11%, and 4.3% (study 2) of patients, respectively.

**dapagliflozin versus placebo as add-on to metformin**

Patients with inadequate glycemic control (HbA1c ≥7% and ≤10%) receiving a dose of at least 1,500 mg/day of metformin (n=546) were randomized to add-on either dapagliflozin 5 mg, dapagliflozin 10 mg, or placebo for 24 weeks. Patients receiving dapagliflozin 5 mg or 10 mg achieved statistically significant improvements in HbA1c and FPG, as well as statistically significant reduction in body weight compared with placebo at week 24 (p<0.0001 for all 3 parameters versus placebo plus metformin).

**dapagliflozin versus glipizide as add-on to metformin**

A 52-week, double-blind, multicenter, active-controlled, noninferiority trial randomized patients receiving metformin monotherapy (minimum dose 1,500 mg/day) and inadequate glycemic control...
(HbA1c ≥ 6.5% and ≤ 10%) to add-on dapagliflozin or glipizide. Initial doses were dapagliflozin 2.5 mg or glipizide 5 mg. Glipizide and dapagliflozin were up-titrated over 18 weeks to optimal glycemic effect (FPG < 110 mg/dL) or to the highest dose level (up to a maximum of 20 mg of glipizide or 10 mg of dapagliflozin) as tolerated by the patients. At the end of the titration period, 87% of patients with dapagliflozin had been titrated to the maximum study dose (10 mg) while only 73% of glipizide patients were receiving the maximum dose (20 mg). The primary endpoint, adjusted mean HbA1c reduction with dapagliflozin compared with glipizide, was statistically non-inferior at 52 weeks. Secondary endpoints included adjusted mean weight loss and proportion of patients experiencing hypoglycemia. Dapagliflozin produced significant adjusted mean weight loss (-3.2 kg) versus weight gain (1.2 kg) with glipizide (p<0.001). The proportion of patients experiencing hypoglycemia was 3.4% for dapagliflozin and 39.7% for glipizide (p<0.001).

**dapagliflozin add-on to a sulfonylurea**

A 24-week placebo-controlled study evaluated dapagliflozin when added-on to glimepiride monotherapy (minimum dose 4 mg) in patients with inadequate glycemic control (HbA1c ≥ 7% and ≤ 10%). Patients (n = 597) were randomized to dapagliflozin 5mg, 10 mg, or placebo, in addition to glimepiride 4 mg per day. In combination with glimepiride, dapagliflozin 10 mg provided statistically significant improvement in HbA1c, FPG, 2-hour post prandial glucose (PPG), and statistically significant reduction in body weight compared with placebo plus glimepiride at week 24.

**dapagliflozin add-on to a thiazolidinedione**

Patients (n=420) on a stable dose of pioglitazone (either 30 mg or 45 mg per day) who had inadequate glycemic control (HbA1c ≥ 7% and ≤ 10.5%) for 12 weeks were randomized to dapagliflozin 5 mg, dapagliflozin 10 mg, or placebo, in addition to their current dose of pioglitazone. In combination with pioglitazone, treatment with dapagliflozin 10 mg provided statistically significant improvements in HbA1c, 2-hour PPG, FPG, the proportion of patients achieving HbA1c < 7%, and a statistically significant reduction in body weight compared with placebo plus pioglitazone.

**dapagliflozin add-on to a DPP-4 Inhibitor with or without metformin**

A total of 452 patients who were either drug naïve or who were treated at baseline with metformin or a dipeptidyl peptidase 4 (DPP-4) inhibitor alone or in combination and who had inadequate glycemic control (HbA1c ≥ 7% and ≤ 10%) participated in a 24-week placebo-controlled study to evaluate dapagliflozin in combination with the DPP-4 inhibitor, sitagliptin, with or without metformin. Patients were stratified based on the presence or absence of background metformin (minimum 1,500 mg per day) and, within each stratum, were randomized to dapagliflozin 10 mg plus sitagliptin 100 mg once daily or placebo plus sitagliptin 100 mg once daily. Prior to randomization, 37% of patients were drug naïve, 32% were on metformin alone, 13% were on a DPP4 inhibitor alone, and 18% were on a DPP4 inhibitor plus metformin. In combination with sitagliptin (with or without metformin), dapagliflozin provided statistically significant improvements in HbA1c, FPG, and a statistically significant reduction in body weight compared with placebo plus sitagliptin (with or without metformin) at 24 weeks.

**dapagliflozin add-on combination therapy with insulin**

A double-blind, placebo-controlled, multicenter trial randomized a total of 71 patients to placebo, dapagliflozin 10 mg or dapagliflozin 20 mg in patients who were on a stable dose regimen of insulin and at least 1 oral antidiabetic agent, such as a metformin with or without a thiazolidinedione. Upon
initiation of dapagliflozin, patients were changed to an open-label therapy with 50% of their usual daily insulin dose. Both doses of dapagliflozin decreased HbA1c, FPG, and PPG compared to placebo and overall adverse events were balanced across all groups.

A 24-week, placebo-controlled, multicenter study examined 808 patients with inadequate glycemic control (HbA1c between 7.5% and 10.5%) who were on a stable insulin regimen (mean dose of at least 30 units/day) and a maximum of 2 oral antidiabetic medications, including metformin. After the initial 24 weeks, a 24-week extension was allowed, as well as an additional 56-week extension period for a total of 104 weeks. In this study, 50% of patients were on insulin monotherapy and 50% were on 1 or 2 oral antidiabetic agents in addition to insulin. Patients were randomized to dapagliflozin 2.5 mg, dapagliflozin 5 mg, dapagliflozin 10 mg, or placebo and stratified according to the presence or absence of background oral antidiabetic agents. The primary endpoint was change in HbA1c from baseline after 24 weeks. Secondary outcomes included changes in body weight, insulin dose, and FPG at 24 weeks. No dose modifications of study medication or other oral antidiabetic medications were allowed during the treatment phase except to decrease the dose of oral antidiabetic medications if hypoglycemia became a concern in patients who had already discontinued insulin. Insulin was down-titrated if 2 or more self-monitored blood glucose readings were 80 mg/dL or less in the first 7 days or < 70 mg/dL after the first 7 days. At week 24, all doses of dapagliflozin once daily resulted in a statistically significant reduction in HbA1c levels compared to placebo. These differences were maintained at 48 weeks. The effect of dapagliflozin on HbA1c was similar in patients treated with insulin alone and patients treated with insulin plus oral antidiabetic agents. Significantly greater decreases in body weight occurred in all the dapagliflozin groups compared to placebo (p<0.001) and these differences were maintained at 48 weeks, as well. Mean daily insulin doses were decreased in all dapagliflozin groups compared to placebo at both 24 and 48 weeks (p<0.001). Higher incidences of urinary tract infections, genital infections, and hypoglycemic events were observed in the dapagliflozin groups compared to placebo. At week 104, 513 patients (63.6%) completed the study. Mean HbA1c changes from baseline at 104 weeks were -0.4% in the placebo group and -0.6 to -0.8% in the dapagliflozin groups. In the placebo group, mean insulin dose increased by 18.3 units/day and weight increased by 1.8 kg at 104 weeks, whereas in the dapagliflozin groups, insulin dose was stable and weight decreased by 0.9 to 1.4 kg. Adverse events, including hypoglycemia, were similar between all groups. Proportions of patients with events suggestive of genital infection and of UTI were higher with dapagliflozin versus placebo (genital infection 7.4% to 14.3% versus 3%; UTI 8.4 to 13.8% versus 5.6%) but most occurred in the first 24 weeks and most were single episodes that responded to routine management.

dapagliflozin as add-on to usual therapy

A randomized, double-blind, 24-week clinical trial with a 28-week extension was performed to assess the efficacy of dapagliflozin in 964 patients with type 2 diabetes mellitus and documented cardiovascular disease (CVD). The study was stratified by age (< 65 and ≥ 65 years). Patients were randomized to dapagliflozin 10 mg or placebo once daily added to their usual care. Total daily insulin doses were reduced by 25% at the start of the study. Primary endpoints were change from baseline in HbA1c and proportion of participants achieving a 3-item endpoint of reduction HbA1c ≥ 0.5%, decrease in body weight of at least 3%, and reduction of systolic blood pressure ≥ 3 mmHg at 24 weeks. Forty-seven percent were aged 65 years and older and 7.7% were 75 years and older, mean duration of type 2 diabetes mellitus was 13 years, mean baseline HbA1c was 8.1%, and approximately 60% of patients on insulin therapy. The placebo-corrected change in HbA1c with dapagliflozin was -0.4% at week 24. The difference in adjusted mean change in body weight was -2.07 kg (p<0.0001) and
the difference in change in mean seated systolic blood pressure was -3.76 mmHg (p=0.025).

Significantly more participants achieved the 3-item endpoint with dapagliflozin than with placebo (10 versus 1.9%, respectively). Similar results were reported in both groups. Hypoglycemia was reported in 28.2% of patients who received dapagliflozin compared to 25.3% who received placebo.

**Empagliflozin (Jardiance) monotherapy**

A randomized, double-blind, placebo-controlled, parallel group study evaluated the efficacy and safety of empagliflozin monotherapy in 986 treatment-naive adults with type 2 diabetes who were inadequately controlled with diet and exercise.\(^96,97\) After a 2-week open-label placebo run-in phase, 986 patients who remained inadequately controlled and had an HbA1c between 7% and 10% were randomized to 24 weeks of daily oral empagliflozin 10 mg or 25 mg, placebo, or sitagliptin 100 mg as a comparator. Patients with HbA1c > 10% in the open-label phase received empagliflozin 25 mg. Primary endpoint was the change in HbA1c from baseline. At Week 24, treatment with empagliflozin 10 mg and 25 mg and sitagliptin provided statistically significant reductions in HbA1c compared to placebo (-0.74, -0.85, -0.73, respectively; \(p < 0.0001\) for all). Significant reductions were also reported with secondary endpoints of fasting plasma glucose (FPG). Patients on empagliflozin (-1.93 kg for 10 mg, -2.15 kg for 25 mg, \(p < 0.001\) for both) experienced significantly greater weight loss than those assigned to sitagliptin (+0.52 kg) and placebo. The incidence of reported hypoglycemic events was low in all groups, and was of mild intensity. Changes in eGFR were small and were similar across all groups. At Week 24, the placebo-adjusted reduction in systolic blood pressure was statistically significant for empagliflozin 10mg (-2.6 mmHg; \(p=0.0231\)) and empagliflozin 25 mg (-3.4 mmHg; \(p=0.0028\)).

**Empagliflozin add-on to metformin (Synjardy)**

In a double-blind, placebo-controlled trial, a total of 637 patients with type 2 diabetes who were inadequately controlled on metformin (≥ 1,500 mg/day or maximum tolerated dose) were randomized to add-on therapy with empagliflozin 10 mg or 25 mg daily or placebo.\(^98,99\) At Week 24, add-on treatment with either dose of empagliflozin resulted in statistically significant reductions compared to placebo in HbA1c (-0.7%, -0.8%, and -0.1%, respectively \(p < 0.0001\)), FPG (-20, -22, and +6 mg/dL), and body weight (-2.5%, -2.9%, and -0.5%; respectively). In addition, treatment with empagliflozin led to a significant reduction in systolic blood pressure compared to placebo (placebo-corrected -4.1 mmHg for empagliflozin 10 mg and -4.8 mmHg for empagliflozin 25 mg; \(p < 0.0001\) for both strengths).

**Empagliflozin plus metformin (Synjardy) versus glimepiride plus metformin**

In a double-blind study, 1,545 patients with inadequately controlled type 2 diabetes with metformin (≥ 1,500 mg/day or maximum tolerated dose) were randomized to add-on with empagliflozin 25 mg daily or glimepiride 1 to 4 mg daily.\(^100,101,102\) At 52 weeks, empagliflozin 25 mg and glimepiride produced similar reductions in HbA1c. Each agent resulted in reductions in FPG (-19 and -9 mg/dL, respectively). Reported changes in body weight were -3.9% for empagliflozin and +2% for glimepiride. The mean daily dose of glimepiride was 2.7 mg (maximal approved dose in the U.S. is 8 mg/day). There was a significant difference in the adjusted mean change in systolic blood pressure between the 2 groups (-3.6 mmHg for empagliflozin versus 2.2 mmHg for glimepiride; \(p < 0.0001\)). In addition, at 104 weeks, empagliflozin was shown to be non-inferior to glimepiride.\(^103\) The incidence of adverse reactions, including serious reactions, was similar between treatment groups.
emagliflozin add-on to metformin [Synjardy] and sulfonylurea

In a 24-week double-blind, placebo-controlled study, 666 patients with type 2 diabetes who were inadequately controlled (HbA1c 7% to 10%) on metformin (≥ 1,500 mg/day or maximum tolerated dose) plus a sulfonylurea (at least half the recommended dose or maximum tolerated dose) were randomized to receive add-on therapy with emagliflozin 10 mg or 25 mg daily, or placebo. Treatment with either dose of emagliflozin provided statistically significant reductions compared with placebo in HbA1c (-0.8%, -0.8%, and -0.2%; respectively; p<0.0001 for both), FPG (-23, -23, and +6 mg/dL, respectively), and body weight (-2.9%, -3.2%, and -0.5%, respectively).

emagliflozin add-on to pioglitazone with or without metformin

In a 24-week double-blind, placebo-controlled study, patients with type 2 diabetes inadequately controlled on metformin (≥ 1,500 mg/day) and pioglitazone (≥30 mg/day) entered an open-label 2-week placebo run-in phase. After which, 498 patients with inadequate glycemic control (HbA1c 7% to 10%) were randomized to daily emagliflozin 10 mg or 25 mg or placebo, in combination with pioglitazone, with or without metformin. Of the patients treated, 75.5% were on background therapy with pioglitazone plus metformin, while the remaining 24.5% were on background pioglitazone alone. Both doses of emagliflozin compared with placebo resulted in statistically significant reductions in HbA1c (-0.6%, -0.7%, and -0.1%, respectively; p<0.0001), FPG (-17, -22, and +7 mg/dL, respectively), and body weight (-2%, -1.8%, and -0.6%, respectively). Empagliflozin reduced HbA1c in patients on background pioglitazone plus metformin and pioglitazone alone. Adverse events experienced were mild or moderate in intensity. A 52-week extension trial is also underway.

emagliflozin add-on to insulin with or without metformin and/or sulfonylureas

A 78-week double-blind, placebo-controlled study included 494 patients with type 2 diabetes inadequately controlled on insulin, with or without oral agents, to evaluate the efficacy of emagliflozin as add-on therapy to insulin. Patients entered a 2-week placebo run-in period on basal insulin (e.g., insulin glargine, insulin detemir, or NPH insulin) with or without metformin and/or sulfonylurea background therapy. Patients with inadequate glycemic control were then randomized to the addition of emagliflozin 10 mg or 25 mg, or placebo. Patients were maintained on a stable dose of insulin during the run-in period, and during the first 18 weeks of treatment. For the remaining 60 weeks, insulin could be adjusted. The mean total daily insulin dose at baseline for emagliflozin 10 mg, 25 mg, and placebo was 45, 48, and 48 units, respectively. Empagliflozin in combination with insulin, with or without metformin and/or sulfonylurea, resulted in statistically significant reductions in HbA1c and FPG and body weight compared to placebo.

emagliflozin as add-on to standard of care

The effect of emagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes was evaluated when added to standard of care in a randomized, placebo-controlled trial. A total of 7,020 patients were randomized to emagliflozin 10 mg or 25 mg or placebo once daily. The primary outcome was composite of death due to cardiovascular causes, or nonfatal myocardial infarction (MI) or stroke. The key secondary outcome included the primary outcome plus hospitalization for unstable angina. The primary outcome occurred in 10.5% of patients in the pooled emagliflozin group (10 mg and 25 mg) and 12.1% of the placebo group (hazard ratio [HR], 0.86; 95% CI, 0.74 to 0.99; p=0.04 for superiority). A significantly lower rate of CV death (3.7% versus 5.9%), hospitalization for heart failure...
(2.7% versus 4.1%), and death from any cause (5.7% versus 8.3%) were reported with empagliflozin compared to placebo. No significant differences in the occurrence of MI or stroke or in key secondary outcomes were reported.

META-ANALYSES

The efficacy and safety of canagliflozin, dapagliflozin, and empagliflozin use in adults with type 2 diabetes was compared in a meta-analysis of 38 randomized controlled trials of 24 weeks or longer (n=23,997).\(^{111}\) Compared to placebo, all 3 agents reduced HbA1c, FPG, and body weight. Canagliflozin 300 mg reduced HbA1c and FPG to a greater extent compared to any dose of the other agents. When each was compared to placebo at their highest doses, canagliflozin 300 mg reduced HbA1c by 0.9% and empagliflozin 25 mg and dapagliflozin 10 mg each reduced HbA1c by 0.7%; FPG was reduced by 1.9 mmol/L, 1.5 mmol/L, and 1.4 mmol/L with canagliflozin, empagliflozin, and dapagliflozin, respectively. Canagliflozin 300 mg and 100 mg increased the risk of hypoglycemia compared to dapagliflozin 10 mg and empagliflozin 10 mg (odds ratios [ORs], 1.4 to 1.6). All inhibitors similarly increased the risk of genital infection. Dapagliflozin 10 mg increased the risk of urinary tract infection compared to empagliflozin 25 mg (OR, 1.4). Similar reductions in body weight were reported for the highest doses of all 3 agents. In addition, canagliflozin 300 mg reduced systolic BP and increased LDL-cholesterol to a greater extent compared to dapagliflozin and empagliflozin at any dose.

A meta-analysis of randomized controlled trials conducted from January 2005 to January 2015 indirectly compared the efficacy of SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes with diet and exercise alone or metformin monotherapy.\(^{112}\) All studies were at least 24 weeks in duration. A greater percentage of patients on monotherapy achieved an HbA1c < 7% on canagliflozin 300 mg than on canagliflozin 100 mg (RR, 0.72%; 95% CI, 0.59 to 0.87) and dapagliflozin 10 mg (RR, 0.63; 95% CI, 0.48 to 0.85); however, there were no significant differences compared with either dose of empagliflozin. A greater reduction in HbA1c was reported with canagliflozin 300 mg compared to the other SGLT-2 inhibitors (mean difference ranged from 0.2% to 0.64%). There were no significant differences in weight reduction. Decreases in systolic blood pressure ranged from 6 mmHg with canagliflozin 300 to 2.6 mmHg with empagliflozin 10 mg. Similar proportions of patients on dual therapy with metformin achieved HbA1c < 7% for all SGLT2 inhibitors. Canagliflozin 300 mg reduced HbA1c more than the other drugs, but statistical significance was only reported versus canagliflozin 100 mg.

Earlier meta-analyses have confirmed efficacy of SGLT2 inhibitors as a class compared to placebo as either monotherapy or add-on therapy, but meta-analyses of high-quality evidence estimating comparative efficacy between these agents are limited.\(^{113,114,115}\)

A meta-analysis evaluated the effects of SGLT2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes.\(^{116}\) Prospective randomized trials of greater than 7 days duration in databases prior to September 30, 2015 comparing an SGLT2 inhibitor with placebo or another active control were included (6 regulatory submissions, n=37,525; 57 studies, n=33,385). Trials evaluating 3 other SGLT2 inhibitors not available in the U.S. were included in addition to the trials with canagliflozin, dapagliflozin, empagliflozin. However, results related to canagliflozin, dapagliflozin, empagliflozin were also presented when available and many of the cardiovascular and mortality outcomes assessed were primarily sourced from trials of canagliflozin, dapagliflozin, empagliflozin. SGLT2 inhibitors were associated with a decrease in major adverse cardiovascular events (RR, 0.84; 95% CI, 0.75 to 0.95; p=0.006), cardiovascular death (RR, 0.63; 95% CI, 0.51 to 0.77; p<0.0001), heart
failure (RR, 0.65; 95% CI, 0.5 to 0.85; p=0.002), and death from any cause (RR, 0.71; 95% CI, 0.61 to 0.83; p<0.001). No statistically significant differences were found in non-fatal myocardial infarction or angina (p=0.18 and p=0.7, respectively). However, a trend toward an increase in non-fatal stroke (RR, 1.3; 95% CI, 1 to 1.68; p=0.049) was found as well as an increased risk of genital infections (RR, 2.88; 95% CI, 2.48 to 3.34; p<0.05). The authors noted that much of the data demonstrating cardiovascular improvement was related to a large outcomes study with empagliflozin driving the meta-analysis results, but they also stated that findings with the other agents also supported their results. The cause of the potential protection associated with these agents is unknown as they have been associated with blood pressure and weight lowering effects in addition to their antihyperglycemic effects, all of which may contribute to a potential mortality benefit. While this meta-analysis is promising, future outcomes trials and meta-analyses are needed to confirm these findings as confidence with each individual agent is limited due to overall limited information on these outcomes.

**SUMMARY**

According to the 2016 American Diabetes Association (ADA) Standards of Medical Care in Diabetes, the selection of medications should be patient-centric and prescribers should consider potential issues such as efficacy, cost, side effects, comorbidities, hypoglycemic risk, and patient preferences. If no contraindication exists and if well tolerated, metformin is the preferred initial treatment for type 2 diabetes. If monotherapy at the maximum tolerated dose does not achieve or maintain the desired HbA1c level over 3 months, either a thiazolidinedione (TZD), sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitor, SGLT2 inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, or insulin should be added. If target HbA1c is still not achieved after an additional 3 months, then an agent from a different group listed should be added.

The 2016 American Association of Clinical Endocrinologists (AACE)/ American College of Endocrinology (ACE) algorithm also continues to recommend metformin as first-line therapy. These guidelines recommend SGLT2 inhibitors as one of the alternatives to metformin for monotherapy and an appropriate add-on to metformin in dual and triple therapy for glycemic control. The SGLT2 drugs may be used as add-on therapy to 2 or 3 other agents, including insulin, in patients who would benefit from weight loss as well.

The SGLT2 inhibitors are efficacious agents in reducing HbA1c, postprandial glucose, and fasting plasma glucose, as well as reducing systolic blood pressure and weight. Since these agents exert their glycemic effects in the kidney, they have limited benefit in patients with chronic kidney disease (CKD). However, in April 2016, based on several safety studies, the FDA concluded that metformin may be safely used in patients with mild renal impairment and some patients with moderate renal impairment. Patients receiving SGLT2 inhibitor therapy are at increased risk of urinary and genital tract infections due to its glycosuria effect. The FDA recently alerted prescribers of an increased risk of bone fracture in patients treated with canagliflozin (Invokana, Invokamet, Invokamet XR). Prescribers should consider all factors that can increase the risk of bone fracture before prescribing canagliflozin. The agency is evaluating the potential for this risk as it relates to dapagliflozin (Farxiga, Xigduo XR) and empagliflozin (Jardiance, Synjardy). Similarly, an increased risk of leg and foot amputations with canagliflozin compared to placebo was found recently, and the FDA is continuing to evaluate this risk. The long-term safety of SGLT2 inhibitors remains to be established.

The first study has been published that evaluated the cardiovascular outcomes associated with SGLT2 inhibitor therapy. The study reported approximately a one-third relative risk reduction for
Available SGLT2 inhibitors include canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance). All 3 products also are available in combination with metformin: canagliflozin/metformin (Invokamet, Invokamet XR), dapagliflozin/metformin ER (Xigduo XR), and empagliflozin/metformin (Synjardy). Warnings and adverse effects of single-component metformin agents also apply to these combination products.

REFERENCES

5 Xigduo XR [package insert]. Wilmington DE; AstraZeneca; August 2016.
6 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
7 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
17 Xigduo XR [package insert]. Wilmington DE; AstraZeneca; August 2016.
18 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
21 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
24 Xigduo XR [package insert]. Wilmington DE; AstraZeneca; August 2016.
28 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
31 Xigduo XR [package insert]. Wilmington DE; AstraZeneca; August 2016.
32 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
34 Invokamet XR [package insert]. Titusville, NJ; Janssen; September 2016.
35 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
52 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
55 Syjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.
58 Xigduo XR [package insert]. Wilmington DE; AstraZeneca; August 2016.
89 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.

REVIEWS


Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
© 2004-2016 Magellan Rx Management. All Rights Reserved.

98 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.

99 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.

100 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.


102 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.


104 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.


106 Synjardy [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.

107 Jardiance [package insert]. Ridgefield, CT; Boehringer Ingelheim; July 2016.


